From Wikipedia, the free encyclopedia
Axcan is a privately-held, leading multinational specialty pharmaceutical company focused on gastroenterology. The Company develops and markets a broad line of prescription products to treat a range of gastrointestinal diseases and disorders such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to pancreatic insufficiency. Axcan's products are marketed by its own specialized sales forces in North America and the European Union and through commercial collaborations in many markets around the world. [1]
In February 2008, Axcan was acquired by TPG Capital, a private investment firm. [2]
[edit] References
[edit] External links
